{"id":"amlodipine-simvastatin","safety":{"commonSideEffects":[{"rate":"7-16","effect":"Headache"},{"rate":"1-10","effect":"Peripheral edema"},{"rate":"4-6","effect":"Flushing"},{"rate":"1-3","effect":"Muscle pain/myalgia"},{"rate":"1-3","effect":"Elevated liver enzymes"},{"rate":"3-7","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine is a dihydropyridine calcium channel blocker that prevents calcium influx into vascular smooth muscle cells, causing vasodilation and reduced peripheral resistance. Simvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides. Together, they address two major cardiovascular risk factors.","oneSentence":"This combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (amlodipine) and lowers cholesterol by inhibiting HMG-CoA reductase (simvastatin).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:01.928Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension with hypercholesterolemia"},{"name":"Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy"}]},"trialDetails":[{"nctId":"NCT06523465","phase":"PHASE4","title":"Statin Combined with Amlodipine Treats Primary Aldosteronism","status":"RECRUITING","sponsor":"Third Military Medical University","startDate":"2024-09-10","conditions":"Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist","enrollment":180},{"nctId":"NCT05893849","phase":"","title":"Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-28","conditions":"Aging","enrollment":624},{"nctId":"NCT02850081","phase":"PHASE3","title":"Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-06-01","conditions":"Carotid Artery Stenosis, Strokes","enrollment":31},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT03489317","phase":"","title":"Gut Microbiomes in Patients With Metabolic Syndrome","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2017-11-27","conditions":"Metabolic Syndrome","enrollment":1000},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01631409","phase":"","title":"Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy","status":"WITHDRAWN","sponsor":"City Hospital No 40, Saint Petersburg, Russia","startDate":"2013-09","conditions":"Coronary Heart Disease (CHD)","enrollment":""},{"nctId":"NCT01011660","phase":"PHASE4","title":"Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2007-10","conditions":"Essential Hypertension","enrollment":13542},{"nctId":"NCT00669435","phase":"PHASE4","title":"Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis","status":"UNKNOWN","sponsor":"University of Pavia","startDate":"2008-04","conditions":"Hypertension","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amlodipine + Simvastatin","genericName":"Amlodipine + Simvastatin","companyName":"University of Pavia","companyId":"university-of-pavia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (amlodipine) and lowers cholesterol by inhibiting HMG-CoA reductase (simvastatin). Used for Hypertension with hypercholesterolemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}